"name","uuid:ID","instanceType","description","label","id","rationale"
"Study Design 1","9e74b6af-deda-4db7-a45b-0da938d56713","StudyDesign","The main design for the study","","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
